There are 2137 resources available
1115P - Association between hospital stays with infection and overall survival in patients treated with ipilimumab, analysis of the French nationwide exhaustive hospital discharge database (PMSI)
Presenter: Pierre-Yves Cren
Session: E-Poster Display
Resources:
Abstract
1116P - Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting
Presenter: C. Lance Cowey
Session: E-Poster Display
Resources:
Abstract
1117P - Immunotherapy in octogenarian and nonagenarian metastatic melanoma patients
Presenter: Bozena Cybulska-Stopa
Session: E-Poster Display
Resources:
Abstract
1118P - Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
Presenter: Almudena García-Castaño
Session: E-Poster Display
Resources:
Abstract
1119P - Targeted treatment and immunotherapy in older patients with advanced melanoma: A single institution real-life experience
Presenter: Carolina Pereira
Session: E-Poster Display
Resources:
Abstract
1120P - Post-approval trials versus patient registries: Comparability of advanced melanoma patients with brain metastases
Presenter: Rawa Ismail
Session: E-Poster Display
Resources:
Abstract
1121P - Factors predicting overall survival (OS) and progression-free survival (PFS) in real-life: Classification and regression tree analysis of a 5-year (5Y) cohort follow-up study of advanced melanoma patients (pts) that have initiated pembrolizumab
Presenter: Philippe Saiag
Session: E-Poster Display
Resources:
Abstract
1122P - Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases
Presenter: Carola Berking
Session: E-Poster Display
Resources:
Abstract
1123P - A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade
Presenter: Jonathan Zager
Session: E-Poster Display
Resources:
Abstract
1124P - Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience
Presenter: Isabella Glitza
Session: E-Poster Display
Resources:
Abstract